Dear Doctor Letter (Rote-Hand-Brief) on Uptravi® (selexipag): contraindication for concomitant administration of strong CYP2C8 inhibitors
2017.06.14
Active substance: selexipag
The company Actelion Pharmaceuticals Deutschland GMBH is circulating information that a contraindication for concomitant administration of Uptravi® (selexipag) and strong inhibitors of CYP2C8 (e.g. gemfibrozil) has been introduced.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN